Medical Dna Labs, LLC
Medical Dna Labs, LLC was paid $107K by Medicaid between Dec 2019 and May 2023, across 28 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 34% of everything it billed.
TAMPA, FL 33609
Next to other Clinical Medical Laboratory providers in Florida
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 520 | $1K | |
| 2020 | 6,324 | $46K | |
| 2021 | 4,538 | $32K | |
| 2022 | 1,499 | $27K | |
| 2023 | 1,118 | $1K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 34% | 1,242 | 1,005 | $36K |
| 81225 | 23% | 522 | 447 | $25K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 12% | 1,448 | 1,096 | $13K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 11% | 729 | 571 | $12K |
| 81355 | 9.5% | 505 | 443 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.3% | 776 | 600 | $2K |
| 81479 | Unlisted molecular pathology procedure | 1.6% | 1,996 | 444 | $2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.1% | 14 | 12 | $1K |
| 80346 | <1% | 229 | 76 | $1K | |
| 81401 | <1% | 1,319 | 450 | $1K | |
| 82955 | <1% | 510 | 440 | $333.12 | |
| 80348 | <1% | 88 | 63 | $261.11 |
16 more codes
| 80356 | <1% | 87 | $261.06 | |
| 80362 | <1% | 87 | $261.06 | |
| 80373 | <1% | 88 | $261.06 | |
| 80365 | <1% | 116 | $245.75 | |
| 80361 | <1% | 145 | $245.75 | |
| 83992 | <1% | 87 | $245.66 | |
| 80358 | <1% | 86 | $238.40 | |
| 80359 | <1% | 145 | $238.00 | |
| 80353 | <1% | 115 | $238.00 | |
| 80324 | <1% | 117 | $238.00 | |
| 81227 | <1% | 527 | $51.96 | |
| 81226 | <1% | 525 | $51.96 | |
| 81291 | <1% | 526 | $47.42 | |
| 81240 | <1% | 521 | $22.68 | |
| 81400 | <1% | 929 | $11.34 | |
| 81241 | <1% | 520 | $11.34 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Charles K Friedman DO PA | St Petersburg, FL | $2.96M |
| West Park Surgery Center LLC | Pinellas Park, FL | $2.37M |
| Florida Pain Relief Group PLLC | Tampa, FL | $1.90M |
| Medical Tox Labs, LLC | Tampa, FL | $655K |
| Texas Pain Relief Group PLLC | Hurst, TX | $507K |
| Physician Partners of America Crna Operations LLC | Hurst, TX | $349K |
| Medhat F. Mikhael, M.D., INC | Fountain Valley, CA | $341K |
| Sun City Center Ambulatory Surgery Center, LLC | Ruskin, FL | $274K |
| Richard L Smith MD PA | Orlando, FL | $74K |
| Merritt Island Outpatient Surgery Center, LLC | Merritt Island, FL | $15K |
| Hurst Ambulatory Surgery Center, LLC | Hurst, TX | $275.62 |
| Pain Institute of Tampa Bay, PLC | Tampa, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.